Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 4, 2011, Pages 1187-1194

  Balan, Raluca ^a   Simion, Nicoleta ^a   Giuşcǎ, Simona Eliza ^b   Grigoraş, Adriana ^a   Gheucǎ Solovǎstru, Laura ^a   Gheorghita V ^a   Amǎlinei, Cornelia ^a   Cǎruntu, Irina Draga ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b LUCIAN BLAGA UNIVERSITY OF SIBIU   (Romania)

Author keywords

COX 2; EGFR; HPV L1 protein capsid; HSIL; LSIL; p16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PTGS2 PROTEIN, HUMAN;

ARTICLE; BIOPSY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PAPILLOMA VIRUS; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRIDAE; RECEPTOR, EPIDERMAL GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; MIRIDAE;

EID: 84855437586     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, Epidemiologic classification of human papillomavirus types associated with cervical cancer, N Engl J Med, 2003, 348(6):518-527.
2. Stanley M, Pathology and epidemiology of HPV infection in females, Gynecol Oncol, 2010, 117(2 Suppl):S5-S10.
3. Carter JR, Ding Z, Rose BR, HPV infection and cervical disease: a review, Aust N Z J Obstet Gynaecol, 2011, 51(2):103-108.
4. Gu W, Ding J, Wang X, Wang X, De Kluyver RL, Saunders NA, Frazer IH, Zhao KN, Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation, Nucleic Acids Res, 2007, 35(14):4820-4832.
5. Melsheimer P, Kaul S, Dobeck S, Bastert G, Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA, Acta Cytol, 2003, 47(2):124-128.
6. Griesser H, Sander H, Hilfrich R, Moser B, Schenk U, Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia, Anal Quant Cytol Histol, 2004, 26(5):241-245.
7. Ortega S, Malumbres M, Barbacid M, Cyclin D-dependent kinases, INK4 inhibitors and cancer, Biochim Biophys Acta, 2002, 1602(1):73-87.
8. Walts AE, Bose S, p16, Ki-67, and BD ProEx™C immunostaining: a practical approach for diagnosis of cervical intraepithelial neoplasia, Hum Pathol, 2009, 40(7):957-964.
9. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M, Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri, Int J Cancer, 2001, 92(2):276-284.
10. Bibbo M, Klump WJ, DeCecco J, Kovatich AJ, Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens, Acta Cytol, 2002, 46(1):25-29.
11. Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, Bliev A, Spitkovsky D, Ermilova V, Kisseljov F, Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells, BMC Cancer, 2004, 4:58.
12. Fiedler M, Campo-Fernández B, Laich A, Moser B, Stöckl P, Jansen-Dürr P, Zwerschke W, Purification and characterisation of the E7 oncoproteins of the high-risk human papillomavirus types 16 and 18, J Virol Methods, 2006, 134(1-2):30-35.
13. Guimarães MC, Gonçalves MA, Soares CP, Bettini JS, Duarte RA, Soares EG, Immunohistochemical expression of p16INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions, J Histochem Cytochem, 2005, 53(4):509-516.
14. Murphy N, Ring M, Heffron CC, King B, Killalea AG, Hughes C, Martin CM, McGuinness E, Sheils O, O'Leary JJ, p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer, J Clin Pathol, 2005, 5(5):525-534.
15. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA, Biological significance of c-erbB family oncogenes in head and neck cancer, Cancer Metastasis Rev, 2005, 24(1):47-69.
16. Pim D, Collins M, Banks L, Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor, Oncogene, 1992, 7(1):27-32.
17. González Martín A, Molecular biology of cervical cancer, Clin Transl Oncol, 2007, 9(6):347-354.
18. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO, Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients, J Clin Oncol, 2002, 20(4):973-981.
19. Kim YM, Park SY, Pyo H, Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells, Mol Cancer Res, 2009, 7(8):1367-1377.
20. Sarian LO, Derchain SF, Yoshida A, Vassallo J, Pignataro F, Lucci De Angelo Andrade LA, Expression of cyclooxygenase-2 (COX-2) and Ki67 as related to disease severity and HPV detection in squamous lesions of the cervix, Gynecol Oncol, 2006, 102(3):537-541.
21. Subbaramaiah K, Dannenberg AJ, Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange, Cancer Res, 2007, 67(8):3976-3985.
22. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla- Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, Busch R, Hermannstädter C, Nährig J, Becker KF, Becker I, Höfler H, Fend F, Luber B, Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system, Mod Pathol, 2004, 17(5):579-587.
23. Allred DC, Harvey JM, Berardo M, Clark GM, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol, 1998, 11(2):155-168.
24. Koss GL, Melamed MR, Koss' diagnostic cytology and its histopathologic bases, Lippincott Williams & Wilkins, Philadelphia, 2006, 318-321.
25. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, Young M, Melnick S, Miotti P, Burk R, Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women, J Natl Cancer Inst, 1999, 91(3):226-236.
26. Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, Wright TC, Incidence of cervical squamous intraepithelial lesions in HIV-infected women, JAMA, 2000, 283(8):1031-1037.
27. Balan R, Giuşcǎ S, Cǎruntu ID, Gheorghita V, Neacşu D, Amǎlinei C, Immunochemical assessment of p16 and HPV L1 capsid protein in cervical squamous intraepithelial lesions, Rev Med Chir Soc Med Nat Iasi, 2010, 114(4):1118-1124.
28. Yildiz IZ, Usubütün A, Firat P, Ayhan A, Küçükali T, Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature, Path Res Pract, 2007, 203(6):445-449.
29. Gurrola-Díaz CM, Suárez-Rincón AE, Vázquez-Camacho G, Buonocunto-Vázquez G, Rosales-Quintana S, Wentzensen N, von Knebel Doeberitz M, P16INK4a immunohistochemistry improves the reproducibility of the histological diagnosis of cervical intraepithelial neoplasia in cone biopsies, Gynecol Oncol, 2008, 111(1):120-124.
30. Guo M, Warriage I, Mutyala B, Patel S, Lin E, Gong Y, Sneige N, Evaluation of p16 immunostaining to predict high-grade cervical intraepithelial neoplasia in women with Pap results of atypical squamous cells of undetermined significance, Diagn Cytopathol, 2011, 39(7):482-488.
31. Kurshumliu F, Thorns C, Gashi-Luci L, P16INK4a in routine practice as a marker of cervical epithelia neoplasia, Gynecol Oncol, 2009, 115(1):127-131.
32. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E, p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis, Cancer Treat Rev, 2009, 35(3):210-220.
33. Missaoui N, Hmissa S, Sankaranarayanan R, Deodhar K, Nene B, Budukh A, Malvi S, Chinoy R, Kelkar R, Kane S, Chauhan M, Kothai A, Kahate S, Fontanière B, Frappart L, p16INK4A overexpression is a useful marker for uterine cervix lesions, Ann Biol Clin (Paris), 2010, 68(4):409-414.
34. Ungureanu C, Socolov D, Anton G, Mihailovici MS, Teleman S, Immunocytochemical expression of p16INK4a and HPV L1 capsid proteins as predictive markers of the cervical lesions progression risk, Rom J Morphol Embryol, 2010, 51(3):497-503.
35. Rocha AS, Bozzetti MC, Kirschnick LS, Edelweiss MI, Antibody anti-p16(INK4a) in cervical cytology, Acta Cytol, 2009, 53(3):253-262.
36. Huang MZ, Li HB, Nie XM, Wu XY, Jiang XM, An analysis on the combination expression of HPV L1 capsid protein and p16INK4a in cervical lesions, Diagn Cytopathol 2010, 38(8):573-578.
37. INK4A expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women, Pathol Int, 2005, 55(8):491-496.
38. Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C, Epidermal growth factor receptor as a biomarker for cervical cancer, Ann Oncol, 2011, 22(10):2166-2178.
39. Feng W, Duan X, Liu J, Xiao J, Brown RE, Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions, Int J Clin Exp Pathol, 2009, 2(3):249-260.
40. Chapman WB, Lorincz AT, Willett GD, Wright VC, Kurman RJ, Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions, Int J Gynecol Pathol, 1992, 11(3):221-226.
41. Nicholson RI, Gee JM, Harper ME, EGFR and cancer prognosis, Eur J Cancer, 2001, 37(Suppl 4):S9-S15.
42. Eijsink JJ, Noordhuis MG, ten Hoor KA, Kok M, Hollema H, de Bock GH, Nijman HW, Schuuring E, Wisman GB, van der Zee AG, The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer, Hum Pathol, 2010, 41(12):1735-1741.
43. West CM, Joseph L, Bhana S, Epidermal growth factor receptor-targeted therapy, Br J Radiol, 2008, 8(Spec No 1): S36-S44.
44. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC, Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors, Brit J Cancer, 2001, 85(7):1023-1031.
45. Munkarah A, Ali-Fehmi R, COX-2: a protein with an active role in gynecological cancers, Curr Opin Obstet Gynecol, 2005, 17(1):49-53.
46. Mitchell A, Newton JM, Brite K, Einspahr J, Ellis M, Davis J, Nuno T, Alberts DS, Garcia F, Cyclooxygenase 2 expression in cervical intraepithelial neoplasia and vulvar cancer, J Low Gen Tract Dis, 2007, 11(2):80-85.
47. Jabbour HN, Sales KJ, Catalano RD, Norman JE, Inflammatory pathways in female reproductive health and disease, Reproduction, 2009, 138(6):903-919.
48. Khunamornpong S, Settakorn J, Sukpan K, Srisomboon J, Ruangvejvorachai P, Thorner PS, Siriaunkgul S, Cyclooxygenase-2 expression in squamous cell carcinoma of the uterine cervix is associated with lymph node metastasis, Gynecol Oncol, 2009, 112(1):241-247.
49. Modugno F, Ness RB, Chen C, Weiss NS, Inflammation and endometrial cancer: a hypothesis, Cancer Epidemiol Biomarkers Prev, 2005, 14(12):2840-2847.
50. Goswami B, Rajappa M, Sharma M, Sharma A, Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies, Intern J Gynecol Cancer, 2008, 18(4):591-599.
51. Hawk ET, Viner JL, Dannenberg A, DuBois RN, COX-2 in cancer - a player that's defining the rules, J Natl Cancer Inst, 2002, 94(8):545-546.
52. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ, Cyclooxygenase-2 is overexpressed in human cervical cancer, Clin Cancer Res, 2001, 7(2):429-434.
53. Farley J, Uyehara C, Hashiro G, Belnap C, Birrer M, Salminen E, Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure, Gynecol Oncol, 2004, 92(2):596-602.
54. Balan R, Amǎlinei C, Giuşcǎ SE, Ditescu D, Gheorghiţǎ V, Crauciuc E, Cǎruntu ID, Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions, Rom J Morphol Embryol, 2011, 52(1):39-43.
55. Saldivar JS, Lopez D, Feldman RA, Tharappel-Jacob R, de la Rosa A, Terreros D, Baldwin WS, COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study, Gynecol Oncol, 2007, 107(1 Suppl 1):S155-S162.
56. Adimi P, Dahl Steffensen K, Schledermann D, Rye Rasmussen E, Jakobsen A, The prognostic importance of EGFR and COX-2 expression in cervix cancer stages IIb- IVa, J Cancer Ther, 2011, 2(1):9-15.
57. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN, Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention, J Clin Oncol, 2005, 23(2):254-266.
58. Half E, Sun Y, Sinicrope FA, Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells, Cancer Lett, 2007, 251(2):237-246.